RxDoctor Payments Data

Lawrence Gooss, DO

Family Medicine · Midlothian, VANPI 1508092487

Payments from drug & device makers

$4,187in general payments, 2019–2025

Across 202 payments — averaging $20.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$512
  • Lilly USA, LLC$480
  • Novo Nordisk$460
  • AbbVie$430
  • Abbott$308
  • Pfizer$274
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$4,187100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,187 in reported general payments places this provider in the 85th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$180,001
Medicare patients
541
Services billed
4,686

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin80$95,707
OzempicSemaglutide83$92,836
EliquisApixaban69$68,623
XareltoRivaroxaban50$57,590
JanuviaSitagliptin Phosphate26$36,504
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$36,251
MounjaroTirzepatide28$29,050
TrulicityDulaglutide12$28,813
MyrbetriqMirabegron31$27,438
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr36$22,283
Synjardy XrEmpagliflozin/Metformin Hcl23$20,958
FarxigaDapagliflozin Propanediol21$18,031
TradjentaLinagliptin27$15,816
Janumet XrSitagliptin Phos/Metformin Hcl14$11,737
Bydureon BciseExenatide Microspheres11$9,137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$118$132,480130 claims
Novo NordiskOzempic$460$92,83683 claims
PfizerEliquis$274$68,62369 claims
GSKTrelegy Ellipta, Anoro Ellipta$125$58,53479 claims
Lilly USA, LLCMounjaro, Trulicity$480$57,86240 claims
MerckJanuvia, Janumet Xr$55$48,24240 claims
Astellas Pharma US IncMyrbetriq$21$27,43831 claims
AstraZenecaFarxiga$512$18,03121 claims
AbbVieSynthroid$430$5,48996 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$3,378379 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Midlothian

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →